# GOVERNMENT OF INDIA MINISTRY OF CHEMICALS AND FERTILIZERS DEPARTMENT OF PHARMACEUTICALS

# LOK SABHA UNSTARRED QUESTION No. 4721 TO BE ANSWERED ON 28<sup>TH</sup> MARCH 2025

#### **Incentives for Pharmaceutical Products**

#### 4721. Shri Sribharat Mathukumilli:

### Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

- (a) the total number of companies from each State that have applied for incentives under the Production Linked Incentive (PLI) Scheme for Pharmaceutical products since its inception;
- (b) the total number of applications approved under the PLI Scheme for Pharmaceutical products, State-wise especially from Andhra Pradesh;
- (c) the total amount of funds allocated and disbursed to various entities under the PLI Scheme for Pharmaceuticals since its inception, State-wise;
- (d) the current status of investments and manufacturing activities initiated by MSMEs under the PLI Scheme for Pharmaceutical products, State-wise; and
- (e) the steps taken to support and promote various entities to maximize their benefits from the PLI Scheme for pharmaceuticals products, particularly in enhancing their competitiveness and export capabilities, State-wise?

### **ANSWER**

## THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS

(SMT. ANUPRIYA PATEL)

(a) to (d): The Government is implementing two Production Linked Incentive (PLI) schemes for pharmaceuticals products. Under the PLI Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India ("PLI Scheme for Bulk Drugs"), PLI is given to boost domestic manufacturing of identified KSMs, DIs and APIs by attracting investments in the sector and thereby reduce India's import dependence in critical APIs. Further, under the PLI Scheme for Pharmaceuticals, PLI is given to increase investment and production of specified categories of pharmaceutical drugs, other than KSMs, DIs and APIs covered under the PLI Scheme for Bulk Drugs.

State-wise details of the number of applications approved for participation in each of the two PLI schemes, the number of approved applicant companies who applied for PLI under each scheme, the amount of funds disbursed under each scheme and the status of investments and the sales made as a result of manufacturing activities of approved micro, small and medium enterprise (MSME) applicants are at Annexure. Funds are not allocated to entities. Disbursement is made by way of PLI to approved scheme participants after due diligence on claims submitted and fee payable to the project management agency for the scheme concerned.

(e): Under the PLI schemes for pharmaceuticals and bulk drugs, investment and production are incentivised based on eligible sales. The selected applicants under the PLI schemes for pharmaceuticals and bulk drugs have received incentive worth ₹4,174.9 crore for investment and sales made. The cumulative sales made under the said schemes is worth ₹2,36,125 crore which includes export worth ₹1,49,832 crore. The incentives have facilitated investment and increased capabilities which is reflecting in sales and exports made.

Annexure referred to in the reply to parts (a) to (d) of the Lok Sabha Unstarred Q. No. 4721 for answer on 28.3.2025, raised by Shri Sribharat Mathukumilli, regarding Incentives for Pharmaceutical Products

Details of the number of applications approved for participation in the PLI Scheme for Bulk Drugs, the number of approved applicant companies who applied for PLI under the scheme, the amount of funds disbursed under the scheme and the status of investments and the sales made as a result of manufacturing activities of approved MSME applicants

(as on 26.3.2025)

State	Number of applications approved for participating in the scheme	Number of approved applicants who have submitted claim for PLI	Funds disbursed to applicants against claims (in crore ₹)	Number of approved applicants who are MSMEs	Investment made by approved MSME applicants (in crore ₹)	Sales made by approved MSME applicants (in crore ₹)
Andhra	10	2	3.76	1	59.45	0.13
Pradesh						
Gujarat	8	2	3.05	5	98.27	21.64
Himachal	1	0	0	0	0	0
Pradesh						
Jammu and	1	0	0	0	0	0
Kashmir						
Karnataka	3	0	0	0	0	0
Madhya	2	0	0	0	0	0
Pradesh						
Maharashtra	6	0	0	5	170.27	72.92
Punjab	1	1	14.9	0	0	0
Rajasthan	1	0	0	0	0	0
Tamil Nadu	2	0	0	1	23.67	0.79
Telangana	13	2	0	1	22.31	3.42
Total	48	7	29.41*	13	373.97	98.9

<sup>\*</sup> The total includes, in addition to funds disbursed to applicants, an amount of ₹7.7 crore disbursed to the project management agency.

Details of the number of applications approved for participation in the PLI Scheme for Pharmaceuticals, the number of approved applicant companies who applied for PLI under the scheme, the amount of funds disbursed under the scheme and the status of investments and the sales made as a result of manufacturing activities of approved MSME applicants

(as on 26.3.2025)

State/UTs	Number of applications approved for participating in the scheme	Number of approved applicants who have submitted claim for PLI	Funds disbursed to applicants against claims (in crore ₹)	Number of approved applicants who are MSMEs	Investment made by approved MSME applicants (in crore ₹)	Sales made by approved MSME applicants (in crore ₹)
Andhra	0	0	0	0	0	0
Pradesh						
Chandigarh	1	1	10	0	0	0
Delhi	1	1	2.47	0	0	0
Gujarat	10	10	1,323.15	1	115	1,894.39
Haryana	1	1	1.63	1	37.08	224.91
Himachal	1	0	0	1	40.62	140.19
Pradesh						
Karnataka	3	2	136.9	2	122	708.25
Madhya	1	1	18.39	0	0	0
Pradesh						
Maharashtra	14	13	1,181.44	6	708.11	5,043.22
Punjab	1	1	15.02	0	0	0
Tamil Nadu	4	3	27.14	2	65.69	220.28
Telangana	18	15	1,437.05	7	1,122.67	5,254.84
Total	55	48	4,159.87*	20	2,211.17	13,486.08

<sup>\*</sup> The total includes, in addition to funds disbursed to applicants, an amount of ₹6.68 crore disbursed to the project management agency.

\*\*\*\*